{
    "nct_id": "NCT03769766",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled Trial of Curcumin to Prevent Progression of Biopsy Proven, Low-risk Localized Prostate Cancer Patients Undergoing Active Surveillance",
    "inclusion_criteria": "* Age between 40-89 years\n* Biopsy proven, low-risk, localized prostate cancer (minimum of 8 cores)\n* May have had biopsy within last 12 months\n* ≤4 separate locations in the prostate involved with cancer. If multiple cores are obtained from same lesion or area than this will count as one location.\n* Gleason score ≤6 with no Gleason pattern 4\n* Clinical stage T1c-T2a/b\n* Serum PSA ≤15 ng/ml\n* Life expectancy > 5 years\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 40 Years\nMust have maximum age of 89 Years",
    "exclusion_criteria": "* Any previous prostate cancer treatment (radiotherapy, chemotherapy, hormonal therapy, oral glucocorticoids, GnRH analogues, prostatectomy)\n* Concurrent or previous use within 6 months of screening of any 5α-reductase inhibitor\n* Use of anabolic steroids or drugs with antiandrogenic properties\n* Prostate volume >150 cm³\n* Patients who are taking antiplatelet, anticoagulant agents or have a history of a bleeding disorder. Patients taking 81 mg of Aspirin will be allowed to enroll with close observation\n* History of gastric or duodenal ulcers or untreated hyperacidity syndromes. Patients on stable doses (2 months of therapy) of GERD medication allowed.\n* Patients who are currently taking Curcumin and are unwilling to stop or plan to take Curcumin during the study\n* Patients with a history of gallbladder problems or gallstones or biliary obstruction, unless patient had cholecystectomy",
    "miscellaneous_criteria": ""
}